Tejal SomvanshiPeptides sold online and through compounding pharmacies as muscle-recovery compounds are widely used in Australian sporting and fitness communities. Most people taking them assume a level of safety that a Victorian coroner’s findings have now sharply challenged. The inquest into the death of Richard Norton — a well-known Australian martial-arts actor who appeared alongside Jackie Chan and Chuck Norris across decades of Hollywood action films — found that his death was triggered by self-injected unapproved peptides.
Norton’s death is believed to be the first confirmed fatality from unregulated peptide use in Australia, according to reports from the Victorian coroner’s process. The distinction between “believed to be” and “confirmed as” matters here: the coroner ruled on the cause in this case, and reports describe it as a first, but there is no central database tracking all peptide-related adverse events in Australia — which is itself part of the problem the coroner’s recommendations are trying to address.
The peptides named in the inquest included BPC-157 and TB-500, which are sold online as tissue-repair compounds, and growth-hormone secretagogues, which trigger the body to release more growth hormone. None of these are approved by the Therapeutic Goods Administration. They are technically research chemicals — substances developed in laboratory settings that have not completed the clinical trial process required for human use. They carry no approved dosing guidance, no manufacturing safety standards enforced at a regulatory level, and no requirement for a doctor to monitor the person taking them.
The coroner has urged the TGA to tighten restrictions on unapproved peptides. Currently, a regulatory grey area allows a commercial pipeline to operate that bypasses the safeguards attached to approved medicines.
The telehealth-to-compounding-pharmacy pipeline
Independent MP Dr Monique Ryan has called for a parliamentary inquiry into what she describes as vertically integrated business models in which online telehealth services and compounding pharmacies are closely connected. The model typically works like this: a patient consults a telehealth platform, sometimes with limited or no face-to-face medical review; a prescription or recommendation is generated; a compounding pharmacy affiliated with the platform sends the product directly to the patient’s address; the patient self-injects at home with no ongoing monitoring.
For approved medicines, this model raises its own concerns — as recent recalls of compounding pharmacy injectable products over sterility defects have demonstrated (https://www.karmactive.com/apothecary-pharma-tirzepatide-injection-sterility-recall/). For unapproved peptides, the risks are compounded further: the compounding process itself is not subject to the same standards as pharmaceutical manufacturing. Batch consistency, sterility, and concentration accuracy are all variables the user cannot verify.
The market for these products has grown in recent years, driven by the same wellness and body-composition concerns that have made approved GLP-1 drugs like semaglutide — better known as Ozempic — hugely in demand. The difference is that GLP-1 drugs have passed years of clinical trials, received TGA approval, and are dispensed under medical supervision with known side-effect profiles. Unapproved peptides skip all of that.
Dr Ryan’s call for an inquiry has gained attention because it targets business structure, not just substance regulation. The concern is that dangerous chemicals are being sold, but also that a commercial model has been built specifically to make it easy for body-conscious men — the market most often targeted — to access them with minimal friction and minimal oversight.
The TGA can tighten scheduling controls on individual compounds, and the coroner’s recommendation points in that direction. But as long as the underlying business model remains intact — online consult, affiliated compounder, direct mail to customer — new compounds will fill any gap left by restricting the old ones.
Australia is not alone in facing regulatory pressure around health products and spending. France has been dealing with the political fallout of health and fiscal decisions this year, as public protests made clear (https://www.karmactive.com/france-bond-yields-protests-limoges-fire-2026/). Regulatory failures that cost lives have a way of cutting through political noise. The men using these compounds are often not teenagers taking risks — they are working adults who believe they are optimising their health. Telling that market it has been poorly served by the companies selling to it is a harder political message than simply banning a chemical.
For anyone currently using peptides obtained through online telehealth and compounding channels, the coroner’s findings are unambiguous. The oversight that regulated medicines carry — manufacturing standards, clinical evidence, prescriber accountability — was never applied to the product being injected. Until it is, the risk remains unquantified and the consequences, as this inquest has shown, can be fatal.
